Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: results + cancer + shows  Related to the article below (Last Update: 8/5/2008)


OverTheLimit.info
Experts Question Prostate Cancer Screening Benefits
eMaxHealth.com, NC -
Screening test results may appear to be normal even though prostate cancer is present. A man who receives a false-negative test result (one that shows there ...
Task Force Says Men Age 75 and Older Should Not Be Screened For ... Earthtimes (press release)
all 554 news articles »
OXiGENE Reports Second Quarter 2008 Results
FOXBusiness - Aug 4, 2008
OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The company's major focus is ...OXGN - OTC:CMTX
Promising early results for new prostate cancer drug
OnMedica, UK -
Sally Burtles, our director of Drug Development said she was ?delighted that this drug, originally developed by us is continuing to show promise and has the ...
Child melanoma shows troubling rise
Baxter Bulletin, AR -
New data from the National Cancer Institute shows that the melanoma-incidence rate for children 18 and younger increased 84 percent from 1975 to 2005. ...
Breast cancer: What you need to know
Food Consumer, IL -
The study of rats show the number of tumors was reduced by up to 61 percent when rats were fed the amount of extract from six apples a day. The results ...
N9GL's RF Safety Column: Hijacking Science
ARRL, CT -
Generally, the results of such a study must be replicated at least once -- preferably by an unrelated scientific laboratory -- to show that the results are ...

Voice of America
Ten Percent of Healthy People Injured from Silent Strokes
Voice of America -
An American study shows that increasing numbers of young women are developing melanoma, the most deadly form of skin cancer. The study did not identify ...
Menstruation is a Disease (And Other Ridiculous Myths Believed by ...
Natural News.com, AZ -
They're the people dropping SSRI pills down their throats and getting mammograms because they think mammography prevents breast cancer (hint: they actually ...
Drug shows promise treating breast cancer
St. Louis Post-Dispatch,  United States - Aug 4, 2008
Naughton said initial results of the Siteman study show Zometa helps decrease the number of cancer cells in the bone marrow of women with localized breast ...
Media scan
Indianapolis Star, United States -
Fighting breast cancer was not a life-altering experience for Shelley Lewis. In Five Lessons I Didn't Learn From Breast Cancer (and One Big One I Did) (New ...
Source: Google News

… cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: Mature results of the EORTC … -
G Stuart, K Bertelsen, C Mangioni, C Trope, K … - Proc Am Soc Clin Oncol, 1998 - asco.org
... ANALYSIS SHOWS A HIGHLY SIGNIFICANT IMPROVED OVERALL SURVIVAL (OS) FOR
CISPLATIN-PACLITAXEL AS FIRST LINE TREATMENT OF ADVANCED OVARIAN CANCER: MATURE ...

[PDF] … and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to … -
G Nishimura, I Terada, T Kobayashi, I Ninomiya, H … - Oncol Rep, 2002 - 147.52.72.117
... FU given to patients with low DPD results in higher ... Besides the anti-cancer effects,
this higher 5-FU ... Actually, many reports (2,3) show that patients with low ...
-

Report of the International Workshop on Screening for Breast Cancer -
SW Fletcher, W Black, R Harris, BK Rimer, S … - jnci, 1993 - jnci.oxfordjournals.org
... Results from two of these trials were statistically significant ... aged 40?49, randomized
controlled trials of breast cancer screening show no benefit 5 ...

Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal … -
KY Chung, J Shia, NE Kemeny, M Shah, GK Schwartz, … - Journal of Clinical Oncology, 2005 - jco.ascopubs.org
... Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not ... AB,
Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. ...

Relevant Prognostic Factors in Gastric Cancer: Ten-Year Results of the German Gastric Cancer Study. -
JR Siewert, K B?ttcher, HJ Stein, JD Roder - Annals of Surgery, 1998 - annalsofsurgery.com
... The results achieved by the Germans ought to be a ... that lymphadenectomy has no role
in cancer and moves us ... I think Dr. Siewert's report shows that cancer is an ...

[PDF] Inactivation of the Mouse Msh2 Gene Results in Mismatch Repair Deficiency, Methylation Tolerance, … -
M Radman, H te Riele - Cell, 1995 - actxdownload.cell.com
... We show that Msh2-deficient cells lack binding to some ... Taken together, these results
suggest that MMR is ... on the etiology and evolution of cancer, we generated ...
-

… Years of Phase III Trials for Patients With Advanced Non-Small-Cell Lung Cancer: Sobering Results -
OS Breathnach, B Freidlin, B Conley, MR Green, DH … - Journal of Clinical Oncology, 2001 - jcojournal.org
... pilot or phase II trials rarely show prolonged survival ... with advanced-stage
non?small-cell lung cancer. ... As promising results from phase II trials are often ...

Tissue Microarray Analysis of {beta}-Catenin in Colorectal Cancer Shows Nuclear Phospho-{beta}- … -
GG Chung, E Provost, EP Kielhorn, LA Charette, BL … - Clinical Cancer Research, 2001 - AACR
... of ?-Catenin in Colorectal Cancer Shows Nuclear Phospho ... a tissue microarray with
650 colorectal cancer specimens was ... These results were correlated with other ...

… 3 (Stat3) and Phospho-Stat3 (Tyr705) in Node-negative Breast Cancer Shows Nuclear Localization Is … -
M Dolled-Filhart, RL Camp, DP Kowalski, BL Smith, … - Clinical Cancer Research, 2003 - AACR
... Tyr705) in Node-negative Breast Cancer Shows Nuclear Localization ... 346 node-negative
breast cancer specimens ... These results were correlated with overall survival ...

… as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North … -
JM Nabholtz, A Buzdar, M Pollak, W Harwin, G … - Journal of Clinical Oncology, 2000 - jcojournal.org
... as first-line endocrine therapy for postmenopausal patients with advanced breast
cancer. The efficacy results are particularly important, as they show that in ...

Source: Google Scholar

Drug Study for Brain Cancer Shows Promising Results

A clinical study conducted at Henry Ford Hospital on the use of a drug to extend the survival of patients with the most common and aggressive type of brain cancer, has yielded results that were significantly better than expected.

The randomized Phase II study focused on patients with glioblastoma multiforme (GBM), whose cancer had recurred after first- or second-line therapy. The study revealed that more than a third who were treated with Avastin (bevacizumab) alone, as well as more than half of those treated with Avastin in combination with the chemotherapy drug irinotecan, lived without further progression of the disease for a period of six months. In addition, no new or unexpected adverse effects from the use of Avastin were observed during the study.

“This is very encouraging news,” says Tom Mikkelsen, M.D., a neuro-oncologist who is the study’s principal investigator at Henry Ford and co-director of the Hermelin Brain Tumor Center. "Historical estimates suggest that only 15 percent of patients with this aggressive type of brain cancer live without their cancer progressing within six months. Although gliomas [fast-growing malignant brain tumors] are nearly always incurable, use of a drug like Avastin may help to buy precious time for patients, as well as to preserve their physical and mental functions longer than was previously possible.”

Avastin is a therapeutic antibody designed to inhibit Vascular Endothelial Growth Factor (VEGF), a protein that stimulates development of new blood vessels in a process known as angiogenesis, while maintaining existing tumor vessels. By binding to VEGF, Avastin acts as an anti-angiogenesis agent that chokes off the blood supply to tumors, which in turn inhibits their growth and metastasis.

The national study is sponsored by Genentech and Henry Ford Hospital is one of the large study sites.

“The same process that makes gliomas so deadly may turn out to be exactly the same thing that makes it possible to slow down their progression,” Dr. Mikkelsen says. "This is a very significant advance in the battle to control these aggressive tumors because it could lead to treatment options where none existed previously for patients with recurrent disease.”

Previously Avastin had been used in combination with chemotherapy as a first-line treatment for metastatic colorectal cancer and lung cancer. Because of its demonstrated success rate with these cancers, Avastin currently is being studied worldwide in more than 300 clinical trials for 20 different tumor types.

“With currently approved therapies, the chances of suppressing GBM are poor at less than 10 percent,” says Dr. Mikkelsen. “This type of targeted therapy using Avastin may prove to be the best new hope we have for helping patients with recurrent disease who previously had few options available to them.”

According to the American Cancer Society (ACS), the five-year survival
rate for patients with GBM is 3 percent, a figure that has not changed in more than 25 years. The ACS estimates there will be 20,500 new cases of brain cancer and 12,740 brain cancer deaths in 2007.
 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.